Publication: Combined isobutylamido thiazolyl resorcinol and low-fluence Q-switched Nd: YAG laser for the treatment of facial hyperpigmentation: A randomized, split-face study
12
Issued Date
2020-01-01
Resource Type
ISSN
14732165
14732130
14732130
Other identifier(s)
2-s2.0-85094194549
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Cosmetic Dermatology. (2020)
Suggested Citation
Vasanop Vachiramon, Kanchana Leerunyakul, Chaninan Kositkuljorn, Pamela Chayavichitsilp Combined isobutylamido thiazolyl resorcinol and low-fluence Q-switched Nd: YAG laser for the treatment of facial hyperpigmentation: A randomized, split-face study. Journal of Cosmetic Dermatology. (2020). doi:10.1111/jocd.13790 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/60104
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Combined isobutylamido thiazolyl resorcinol and low-fluence Q-switched Nd: YAG laser for the treatment of facial hyperpigmentation: A randomized, split-face study
Other Contributor(s)
Abstract
© 2020 Wiley Periodicals LLC Background: Isobutylamido thiazolyl resorcinol (ITR) is a novel anti-tyrosinase recently shown to be effective in the treatment of hyperpigmentation. Low-fluence Q-switched Nd:YAG 1064-nm laser (LFQS) has proven to be effective for various hyperpigmentary conditions. However, there is no study on the efficacy and safety of combined ITR and LFQS treatment. Objectives: To compare the efficacy and safety of combined ITR and LFQS with LFQS monotherapy for facial hyperpigmentation. Materials and Methods: Patients with symmetrical facial hyperpigmentation were treated with five sessions of once weekly LFQS on the whole face. One side was randomly treated with ITR and the other side received a placebo cream for 12 weeks. Patients were followed for 8 weeks after the last laser treatment. Relative lightness index (RL*I), Facial Hyperpigmentation Severity Score on the malar area (FHSSm), patient satisfaction, recurrence, and adverse events were recorded. Results: Twenty-four patients completed the study. Both sides demonstrated significant reductions of mean RL*I and mean FHSSm from baseline (P <.01). At the 4th week, the ITR-treated side showed more improvement of mean RL*I than the placebo-treated side (62.5% vs 47.3% improvement, P <.05). The mean FHSSm on the ITR-treated was reduced at a significantly higher percentage than the placebo-treated side (54.4% vs 40.2% reduction, P <.05). Partial recurrence was observed on both sides. No serious side effects were noted. Conclusion: Combined ITR and LFQS therapy was more superior than LFQS monotherapy in the treatment of facial hyperpigmentation. ITR may serve as adjuvant for patients with such condition.